About

Simplants – AI-driven Medtech Platform for Sales, Procurement, and Inventory Optimization

Healthcare systems worldwide are under immense pressure: rising costs, chronic staff shortages, and overloaded processes. At the same time, the medical device industry — a €600 billion global market — suffers from massive inefficiencies. Nearly €30 billion is wasted every year through manual, siloed, and non-data-driven workflows. Hospitals hold excessive inventory to avoid shortages, manufacturers tie up capital in consignment stock and loaner sets, and both sides spend countless hours on administrative work instead of focusing on patients and innovation.

Simplants was founded in Hamburg in 2025 by experts from eCommerce, medtech, hospital management, and IT to tackle this structural problem. Backed by €2.2 million in seed funding, Simplants is building the digital backbone for medical device sales and procurement — a platform that combines taxonomy, ontology, and transaction logic to turn complexity into clarity.

Product and Technology

At its core, Simplants provides a marketplace-enabled sales and procurement platform that harmonizes product data, integrates seamlessly with legacy systems (ERP, WMS, HIS/KIS, production systems), and digitalizes transactions along the entire supply chain.

Taxonomy – Based on decades of eCommerce categorization expertise, Simplants has developed the first scalable taxonomy for medical devices, enabling structured, comparable product data across manufacturers and hospitals.

Ontology – Building on the taxonomy, Simplants processes live data flows from ERP and hospital systems. This creates a closed loop of data → transactions → analytics → prediction, powering AI-driven recommendations for demand, substitutions, expiry risk, and allocation.

Integration – Simplants seamlessly connects with existing ERP etc. systems through APIs. This ensures immediate usability without requiring hospitals or manufacturers to replace their ERP.

Transactions – The platform supports orders, shipments, returns, claims, consumption data, and in-field transfers. Unlike catalog-only B2B marketplaces, Simplants digitalizes existing buyer–supplier flows end-to-end before unlocking open marketplace functionality.

Market Focus and Rollout

Simplants is launching in a clearly defined initial market: the €500 million spinal implant sector in Germany. This niche combines high complexity, strong inefficiencies, and measurable financial impact. Together with launch partner Silony Spine, a leading spinal implant manufacturer, Simplants has developed and validated the taxonomy and extended it to additional suppliers and product groups.

In October 2025, the first hospital rollout will go live with a German hospital group performing several thousand spinal surgeries annually. From day one, Simplants will capture millions of euros in gross merchandise volume (GMV), proving its ability to integrate, optimize, and scale.

Following the spinal implant vertical, Simplants will expand into other implant categories and gradually across broader medical device groups. The geographic rollout begins in Germany, extends across Europe, and — following its customers — into the U.S. market from.

Impact and Value Proposition

Hospitals reduce expiry losses, avoid stockouts, optimize storage, and minimize administrative workload. They free up working capital while maintaining or even improving supply security.

Manufacturers lower consignment and loaner levels, reduce capital bound in field inventory, and increase sales efficiency. Sales teams spend less time on manual admin and more on growth.

Healthcare Systems benefit from structural savings: studies confirm that up to 20% of medical device costs can be avoided. This directly reduces waste of public funds and relieves pressure on overstretched health budgets.

Differentiation

Simplants is not “another marketplace.” Simplants starts where the majority of spend happens: by embedding into existing procurement and sales processes, removing inefficiencies, and building trust with hospitals and suppliers. Only once the infrastructure is in place does Simplants unlock marketplace capabilities, followed by ecosystem services with logistics, financing, and compliance partners.

Leadership

Simplants is led by CEO & Co-Founder Andreas du Plessis, who has been building digital businesses since the early 2000s — from B2C eCommerce to marketplaces and later B2B platforms. His core insight: a transactional marketplace can only succeed if it rests on fully integrated system connections across all participants, without data or process gaps, and with silos removed.

Vision

Simplants reduces costs for hospitals and manufacturers by up to 20%, while ensuring higher supply security for patients. Over time, the platform’s predictive models will become the industry’s data backbone.